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Abstract  
Cellular senescence is often accompanied by the extensive production of many 
secretory proteins, which mediate the diverse effects of senescence on the tissue 
microenvironment. The mechanistic target of rapamycin (mTOR), a master regulator 
of protein synthesis, controls this secretory phenotype of senescence through 
modulating translation, transcription and stabilization of mRNA. 
 
 
 
 
 
 
  
A simplistic description of cellular senescence is a state of ‘permanent’ proliferative 
arrest. This cell-autonomous aspect of senescence has implications in cancer and 
ageing: roles attributed to a tumour suppressive function and a reduction in tissue 
regenerative capacity, respectively. Increasing attention, however, has been focused 
on the non-cell-autonomous activities of senescent cells, which occur primarily 
through the senescence-associated secretory phenotype (SASP)
1
. The SASP involves 
a large number of secretory factors, including pleiotropic cytokines, growth factors, 
and extracellular matrix (ECM) proteins and proteases, providing profound and 
diverse impacts on the tissue microenvironment. The SASP modulates many aspects 
of tumorigenesis, including: the immune reaction; the proliferative capacity of 
neighbouring cells (and of themselves); ECM integrity, and; vascularity. Therefore, 
senescence as a whole is not merely a tumour suppressor, but rather a complex 
‘tumour modulator’. It has become evident that the SASP is also an integral part of 
more physiological processes such as embryonic development and wound healing
1
. 
Therefore, understanding how the SASP is regulated and how to manipulate the SASP 
is a central issue in cancer biology and perhaps any other pathology that involves 
disruption of tissue homeostasis. Two recent studies
2,3
, including one in this issue
3
, 
now provide evidence that the mechanistic target of rapamycin (mTOR) kinase, a 
master regulator of protein synthesis, controls SASP regulatory modules, which 
involve mRNA translation, transcription and stabilisation. 
 
mTOR complex 1 (mTORC1) senses nutrients, growth factors and other 
environmental cues, and controls cell growth and proliferation through promoting 
anabolic metabolism
4
. mTORC1 has been implicated in senescence, but the outcome 
of manipulating mTOR activity during senescence appears to vary depending on the 
model
5-8
. In addition, although a positive relationship between mTORC1 activity and 
the SASP has been suggested
6,9
, the mechanism(s) for this correlation were unclear. 
Using rapamycin on human fibroblasts, Laberge et al. first show that the secretion of 
major components of the SASP, including the pro-inflammatory cytokine IL-6, are 
mTOR dependent
2
. This is not simply due to a general reduction of protein synthesis 
occurring upon mTOR inhibition, since these rapamycin-sensitive SASP components 
are mostly modulated at the mRNA level
2
. The transcription of the SASP components 
is largely regulated through complex positive feedback loops between pro-
inflammatory cytokines and the transcription factor NF-kB, conferring local 
amplification on the pro-inflammatory cascade. In the context of senescence, the same 
group previously showed that IL-1, which is mostly bound to the cell surface, is an 
upstream regulator of a pro-inflammatory network within the SASP through 
activation of NF-kB
10
. Consistent with these observations, Laberge et al. show that 
rapamycin treatment attenuates the up-regulation of IL-1 during senescence but, in 
contrast to other rapamycin-sensitive SASP components, this reduction is primarily 
due to translation rather than transcription. They proposed that mTOR facilitates IL1A 
(encoding IL-1) translation, thereby activating NF-B. This triggers the 
amplification of the downstream pro-inflammatory cytokine network through positive 
feedback between NF-B and the cytokines, including IL-1 (tentatively termed ‘IL-
1 model’ in this review, Figure 1b).   
 
This appears to be only one side of the story, however. In this issue, Herranz et al. 
provide a distinct and unexpected view on mTOR’s regulation of the SASP3. They 
identified rapamycin through a small molecule screen for SASP inhibitors. Similar to 
the study by Laberge et al.
 2
, they also observed that a reduction of mRNA levels 
upon mTOR inhibition is more prominent than the effect on translation for most 
SASP components analysed. However, this reduction in mRNA levels appears to be 
caused by enhanced mRNA degradation. They identified MAPKAPK2 (also known 
as MK2) as a specific target of mTOR-regulated translation during senescence. 
MAPKAPK2, a downstream effector of p38 MAPK, has been shown to 
phosphorylate the RNA-binding protein ZFP36L1 to inhibit its AU-rich element 
(ARE)-mediated mRNA decay (AMD) activity
11
. They propose a model that mTOR 
specifically promotes MAPKAPK2 translation during senescence, thereby inhibiting 
the AMD activity of ZFP36L1, which targets some SASP components (tentatively 
termed ‘MK2 model’ in this review, Figure 1b).  
 
How can we reconcile these two models? Although Herranz et al. demonstrate a 
significant down-regulation of IL1A mRNA upon mTOR inhibition in the ‘MK2 
model’, they also show a preferential reduction of translation within SASP 
components, including IL-1 (although IL-1 is reportedly localised at cell surface, 
we include IL-1 as a SASP components in a broad sense in this review) 3. Although 
exactly which mRNAs encoding SASP components are directly degraded through 
ZFP36L1-mediated AMD remains to be elucidated, IL1A appears to have a relatively 
ARE-rich 3’ UTR3. Conversely, in the ‘IL-1 model’, the levels of IL1A mRNA 
appear to be slightly reduced by rapamycin treatment, at least at an early time point 
after senescence induction
2
. These results perhaps imply a cooperative contribution of 
both mechanisms. It is notable that the primary senescence models used in these 
studies are different: DNA damage- (the IL-1 model) or oncogene-induced (the 
MK2 model) senescence. Thus it is possible that the relative contributions of these 
two models might be different between the experimental systems. In addition, similar 
to mTOR activity, MAPKAPK2 activation is dynamic during OIS establishment
3
, 
thus the balance between these models might shift during the course of senescence. 
Although both studies use several means to inhibit mTOR activity, the IL-1 model 
mostly relies on the use of rapamycin, an allosteric inhibitor of mTORC1, which 
partially inhibits the phosphorylation of eIF4E-binding proteins (4E-BPs), and is thus 
a weaker inhibitor of mTOR-mediated Cap-dependent translation initiation compared 
to the ATP-competitive mTOR kinase inhibitors, such as Torin1, which was the 
primary compound used to define the MK2 model
4
. It would be important to 
systematically compare the effects of both types of inhibitors on differential 
regulation of translation during senescence.  
 
In both models, it is not entirely clear how the specificity of mTOR-dependent 
regulation of IL1A and MAPKAPK2 translation, is achieved, since both transcripts 
lack the 5’ terminal oligopyrimidine (TOP) or TOP-like motifs, which characterises 
the mRNAs more sensitive to mTORC1 inhibition
2,3,12
. Nevertheless, a recent study, 
which performed a genome-wide profiling of Torin1-sensitive mRNA translation in 
mouse embryonic fibroblasts using the Ribo-seq technology, identified Mapkapk2 as 
one of the most affected transcripts
12
. Interestingly, instead of the TOP(-like) motifs, 
Laberge et al. predict a highly stable secondary structure downstream of the AUG in 
the IL1A transcript, and suggested that the RNA helicase activity downstream of 
mTORC1 might be involved in regulating such structured mRNAs. This idea requires 
experimental validation. It would be interesting to know whether MAPKAPK2 and 
other ‘non-TOP(-like)’ mRNAs that are sensitive to mTOR inhibition, identified in 
the Ribo-seq studies, contain such a secondary structure
12,13
. 
 
What is in vivo relevance of these studies? An important and often elusive question 
about the in vivo SASP is the origin of the senescent cells: tumour or stromal, for 
instance. Both studies first focus on the dark side of the SASP factors derived from 
stromal senescence (see ‘1’ in Figure 1a). One way to address this question would be 
using a xenograft mouse model, where co-injected senescent fibroblasts enhance, 
likely through the SASP, tumour development of the subcutaneously injected tumour 
cell lines. mTOR inhibition
2,3
 or the constitutive activation of ZFP36L1
3
 specifically 
in senescent fibroblasts blunts the enhancement of tumorigenesis in this model. In 
practice, however, chemotherapy in cancer patients is likely to cause both cell death 
and senescence either in cancer or stromal cells. This might confer confounding 
effects through the tumorigenic aspect of the SASP, but a combination therapy of 
standard chemotherapy and mTOR inhibitors might alleviate the risky part of the 
senescence induction. Of note, both studies show that mTOR inhibition suppresses the 
SASP but does not overcome the proliferative arrest. The reason for this is not clear, 
but, as the authors in these studies speculate, it might be due to the well-recognised 
anti-proliferative effects of mTOR inhibition and/or the heterogeneous nature of the 
SASP components. This point is touched on by the Laberge et al. study
2
. In a similar 
xenograft model, the co-administration of rapamycin and a chemotherapeutic drug to 
the mice injected with a tumour cell line, with or without ‘normal’ fibroblasts, 
exhibited a better outcome than chemotherapy alone, in conditions where rapamycin 
alone has no benefit.  
 
The discovery of the additional benefits of mTOR inhibition, i.e. anti-SASP activity, 
is encouraging, especially considering that anti-proliferative activity of mTOR 
inhibitors has already been exploited in clinical and/or preclinical studies in some 
types of cancer. However, it is critical to consider both the cell-autonomous and non-
cell-autonomous activities of senescence in order to aim for the maximal, or optimal, 
benefits of senescence-induction during cancer therapy. It has been shown that the 
SASP can also be tumour suppressive not only in preneoplastic tumours (represented 
by OIS) but also full-blown cancer contexts, through both anti-proliferative effects 
(see ‘2, 3’ in Figure 1a) and through the activation of the immune surveillance of 
senescent cells (see ‘4’ in Figure 1a)14,15. Although the data from the current studies 
suggest that mTOR inhibition does not reverse the proliferative arrest, further 
investigation would be required to determine the stability of the arrest. Indeed, it was 
previously suggested that mTOR inhibition diverts senescence to quiescence
5
. mTOR 
activation triggers several negative feedback signals towards the PI3K pathway, 
which can be activated by mTOR inhibition
4
. For cancer therapy, this is one rationale 
for the use of mTOR/PI3K dual inhibitors, and the same logic would also apply to 
mTOR inhibition to block the SASP, and yet to reinforce senescence arrest. In the 
mouse liver OIS model, where one can evaluate the induction and immune-mediated 
elimination of OIS hepatocytes
15
, Herranz et al. showed that rapamycin treatment in 
mice leads to an accumulation of oncogene-expressing hepatocytes with reduced 
immune cell infiltration, but the number of cells positive for senescence markers was 
reduced
3
. The data are consistent with the proposed function of mTOR as a positive 
regulator of the SASP, but the long-term OIS arrest after rapamycin treatment in this 
model remains to be validated. Careful consideration of mTOR inhibition of the 
SASP either by rapamycin analogs, ATP competitors, or even mTOR/PI3K dual 
inhibitors might extend its applications in cancer therapy.  
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Figure legend 
Figure 1 mTOR regulation of the SASP. (a) Schematic view of the diverse 
downstream effects of the SASP. The SASP can be pro-tumorigenic (1) or tumour 
suppressive either through reinforcing senescence arrest (2, 3) or facilitating 
elimination of senescent cells by immune cells (4) (see text for details). The SASP 
can also affect the tumour microenvironment through modulating the extracellular 
matrix (ECM) integrity. (b) Integral view of the two proposed models: ‘IL-1 model’ 
(left) and ‘MK2 model’ (right). 
 
 
